参考文献/References:
［1］ NICHOLSON B，NOBLE J，FOROOGHIAN F，MEYERLE C.Central serous chorioretino-pathy：update on pathophysiology and treatment［J］.Surv Ophthalmol，2013，58(2)：103-126.
［2］ RUIZ-MORENO JM，LUGO FL，ARMAD F，SILVA R，MONTERO J，AREVALO JF，et al.Photodynamic therapy for chronic central serous chorioretinopathy［J］.Acta Ophthalmol，2010，88(3)：371-375.
［3］ LEE PY，KIM KS，LEE WK.Severe choroidal ischemia following photodynamic therapy for pigment epithelial detachment and chronic central serous chorioretinopathy［J］.Jpn J Ophthalmol，2009，53(1)：52-56.
［4］ 李鹏程，盛双燕，彭冲，张樱，王智.半剂量光动力疗法治疗慢性中心性浆液性脉络膜视网膜病变［J］.中华眼底病杂志，2011，27(4)：327-330.
LI PC，SHENG SY，PENG C，ZHANG Y，WANG Z.Half-dose photodynamic therapy for chronic central serous chorioretinopathy［J］.Chin J Ocul Fundus Dis，2011，27(4)：327-330.
［5］ 吴敏，胡竹林，薛黎萍，李云琴，肖丽波.半剂量维替泊芬和半能量PDT治疗慢性中心性浆液性脉络膜视网膜病变［J］.眼科新进展，2015，35 (7)：646-648.
WU M，HU ZL，XUE LP，LI YQ，XIAO LB.Half-dose verteporfin and half laser power PDT for chronic central serous chorioretinopathy［J］.Rec Adv Ophthalmol，2015，35 (7)：646-648.
［6］ 吴秀秀，谢琳，游志鹏.光动力治疗中心性浆液性脉络膜视网膜病变的研究进展［J］.眼科新进展，2016，36(12)：1180-1183.
WU XX，XIE L，YOU ZP，Research progress on photodynamic therapy for central serous chorioretinopathy［J］.Rec Adv Ophthalmol，2016，36(12)：1180-1183.
［7］ CHAN WM，LAM DS，LAI TY，TAM BS，LIU TD，CHAN CK.Choroidal vascular remodelling in central serouschorioretinopathy after indocyanine green guidedphotodynamic therapy with verteporfin：a novel treatment atthe primary disease level［J］.Br J Ophthalmol，2003，87(12)：1453-1458.
［8］ ZHAO MW，ZHOU P，XIAO HX，LV YS，LI CA，LIU GD，et al.Photodynamic therapy for acute central serous chorioretinopathy：the safe effective lowest dose of verteporfin［J］.Retina，2009，29(8)：1155-1161.
［9］ ZHAO M，ZHANG F，CHEN Y，DAI H，QU J，DONG C，et al.A 50% vs 30% dose of verteporfin(photodynamic therapy) for acute central serous chorioretinopathy：one-year results of a randomized clinical trial［J］.JAMA Ophthalmol，2015，133(3)：333-340.
［10］ REIBALDI M，CARDASCIA N，LONGO A，FURINO C，AVITABILE T，FARO S，et al.Standard-fluence versus low-fluence photodynamic therapy in chronic central serous chorioretinopathy：a nonrandomized clinical trial［J］.Am J Ophthalmol，2010，149(2)：307-315.
［11］ PRYDS A，LARSEN M.Choroidal thickness following extra fovealphotodynamic treatment with verteporfin in patients with central serous chorioretinopathy［J］.Acta Ophthalmol，2012，90(8)：738-743.
相似文献/References:
[1]李娟娟 李燕.慢性中心性浆液性脉络膜视网膜病变视网膜色素上皮细胞萎缩轨迹的临床观察[J].眼科新进展,2013,33(8):000.
[2]游慧,张学东.激光治疗中心性浆液性脉络膜视网膜病变的新进展[J].眼科新进展,2016,36(3):297.[doi:10.13389/j.cnki.rao.2016.0081]
YOU Hui,ZHANG Xue-Dong.Recent advances in laser for central serous chorioretinopathy[J].Recent Advances in Ophthalmology,2016,36(4):297.[doi:10.13389/j.cnki.rao.2016.0081]
[3]廖丹,许立帅,戴乐,等.577 nm阈下微脉冲激光治疗黄斑中心凹渗漏的慢性中心性浆液性脉络膜视网膜病变[J].眼科新进展,2018,38(2):139.[doi:10.13389/j.cnki.rao.2018.0030]
LIAO Dan,XU Li-Shuai,DAI Le,et al.Subthreshold micropulse yellow laser (577 nm) for chronic central serous chorioretinopathy with foveal leakage[J].Recent Advances in Ophthalmology,2018,38(4):139.[doi:10.13389/j.cnki.rao.2018.0030]
[4]陈莲,何珂,李晓清,等.非那雄胺在慢性中心性浆液性脉络膜视网膜病变患者中的应用[J].眼科新进展,2020,40(5):474.[doi:10.13389/j.cnki.rao.2020.0109]
CHEN Lian,HE Ke,LI Xiaoqing,et al.Clinical effect of Finasteride on chronic central serous chorioretinopathy[J].Recent Advances in Ophthalmology,2020,40(4):474.[doi:10.13389/j.cnki.rao.2020.0109]
[5]肖艳辉,刘高勤,夏蔚.慢性中心性浆液性脉络膜视网膜病变与息肉样脉络膜血管病变多模式影像学特征的比较[J].眼科新进展,2020,40(12):1139.[doi:10.13389/j.cnki.rao.2020.0253]
XIAO Yanhui,LIU Gaoqin,XIA Wei.Multimodal imaging comparison of chronic central serous chorioretinopathy and polypoidal choroidal vasculopathy[J].Recent Advances in Ophthalmology,2020,40(4):1139.[doi:10.13389/j.cnki.rao.2020.0253]
[6]吴敏,胡竹林,薛黎萍,等. 半剂量维替泊芬和半能量PDT治疗慢性中心性浆液性脉络膜视网膜病变[J].眼科新进展,2015,35(7):646.[doi:10.13389/j.cnki.rao.2015.0176]
WU Min,HU Zhu-Lin,XUE Li-Ping,et al. Half-dose verteporfin and half laser power PDT for chronic central serous chorioretinopathy[J].Recent Advances in Ophthalmology,2015,35(4):646.[doi:10.13389/j.cnki.rao.2015.0176]